Latest Capital Raising News

Novo Resources Corp has closed Tranche 2 of its placement, raising approximately C$1.93 million and issuing options to joint lead managers and participants, while Northern Star retains a near 10% stake.

Magnum Mining pivots to exploration-led growth, focusing on its Brazilian Piracanjuba rare earth project with a major drilling campaign and fresh leadership, supported by a $7 million capital injection.

ReadCloud Limited’s 1H26 results reveal robust growth in school-focused businesses, with cash receipts up 22% and operating cash flow rising 10%, positioning the company to outperform its FY26 earnings guidance.

Pure Resources (ASX: PR1) has closed a $3 million placement, issuing 12 million shares after shareholder approval, while also issuing options and advisory shares to support exploration and cutting-edge carbon nanotube fibre research.

Botala Energy’s Pitse Pilot well 3.5B at the Serowe CBM Project in Botswana has reached total depth, intersecting coal seams as predicted and advancing toward flow testing and commercial production.

Galan Lithium has finished commissioning at its Hombre Muerto West project in Argentina, processing its first lithium chloride and aiming for product sales in the second half of 2026. The company is also preparing to expand production capacity by 30% in early 2027.

VRX Silica has kicked off a $6.23 million renounceable entitlement offer, underwritten to $2 million, to fund key development activities at its Arrowsmith North silica sand project including a strategic property purchase and engineering works.

Accelerate Resources has raised A$2 million in a two-tranche placement to fund aggressive exploration at its Balagundi Gold and Woodie Woodie North Manganese projects, aiming for a busy news flow through 2026.

Terragen Holdings secures a landmark supply agreement for its probiotic and biostimulant products with Ravensworth Feedlot, alongside a $2.8 million funded trial at Mort & Co’s Grassdale feedlot to validate its probiotic’s impact on cattle performance.

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.

Beonic Ltd (ASX:BEO) has initiated a $3 million pro-rata renounceable entitlement offer at $0.08 per share, partially underwritten by Alpine Capital, to shore up working capital and repay shareholder loans. The offer carries potential dilution of 35.7% for non-participating shareholders and may increase the Thorney Group's voting power significantly.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.